[go: up one dir, main page]

IN2014DN06737A - - Google Patents

Info

Publication number
IN2014DN06737A
IN2014DN06737A IN6737DEN2014A IN2014DN06737A IN 2014DN06737 A IN2014DN06737 A IN 2014DN06737A IN 6737DEN2014 A IN6737DEN2014 A IN 6737DEN2014A IN 2014DN06737 A IN2014DN06737 A IN 2014DN06737A
Authority
IN
India
Prior art keywords
composition
formulated
present
administration
provides
Prior art date
Application number
Inventor
Sadasivan Vidyasagar
Paul Okunieff
Lurong Zhang
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of IN2014DN06737A publication Critical patent/IN2014DN06737A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/20Elemental chlorine; Inorganic compounds releasing chlorine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides therapeutic compositions and methods for treating gastrointestinal diseases and conditions such as diarrhea for providing rehydration for correcting electrolyte and fluid imbalances and/or for improving small intestine function. In one embodiment the present invention provides a composition formulated for enteral administration wherein the composition does not contain glucose. In a preferred embodiment the composition is formulated for administration as an oral rehydration drink.
IN6737DEN2014 2012-02-08 2013-02-08 IN2014DN06737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596480P 2012-02-08 2012-02-08
PCT/US2013/025294 WO2013119917A1 (en) 2012-02-08 2013-02-08 Materials and methods for treating diarrhea

Publications (1)

Publication Number Publication Date
IN2014DN06737A true IN2014DN06737A (en) 2015-05-22

Family

ID=48948047

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6737DEN2014 IN2014DN06737A (en) 2012-02-08 2013-02-08

Country Status (15)

Country Link
US (4) US20140377374A1 (en)
EP (1) EP2812007B1 (en)
JP (1) JP6084238B2 (en)
KR (2) KR20140120941A (en)
CN (1) CN104093410B (en)
AP (1) AP3941A (en)
AU (1) AU2013216871B2 (en)
BR (1) BR112014019350B1 (en)
CA (1) CA2863388C (en)
EA (1) EA034014B1 (en)
ES (1) ES2862392T3 (en)
HK (1) HK1204290A1 (en)
IN (1) IN2014DN06737A (en)
MX (1) MX368543B (en)
WO (1) WO2013119917A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030970B8 (en) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. COMPOSITION FOR RESTORING THE FINE INTESTINE FUNCTION, METHODS OF ITS PREPARATION AND APPLICATION
MX361647B (en) 2013-03-11 2018-12-13 Univ Florida Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications.
EP3616689A1 (en) 2014-11-24 2020-03-04 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
BR112019006742A2 (en) 2016-10-04 2019-09-03 Entrinsic Health Solutions Inc amino acid compositions and uses thereof
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating diarrhea
CN115916185B (en) * 2020-06-02 2025-09-26 佛罗里达大学研究基金会公司 Preparations and methods for treating diarrhea
JP2023533617A (en) * 2020-07-02 2023-08-03 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド Formulations and methods of use thereof for promoting hydration
CN118369093A (en) * 2021-05-28 2024-07-19 可口可乐公司 Amino acid hydrate preparations and methods of use
CN115531363B (en) * 2021-06-30 2024-03-29 中国科学技术大学 Pharmaceutical compositions for preventing, inhibiting or treating rotavirus infection and uses thereof
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JP3301646B2 (en) * 1993-03-19 2002-07-15 シスメックス株式会社 Reagent for immature cell measurement
AU706195B2 (en) * 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
JP4255656B2 (en) * 2001-09-17 2009-04-15 株式会社メニコン Ophthalmic solution and contact lens solution
US20030143293A1 (en) * 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (en) * 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd Electrolyte composition
DK175877B1 (en) * 2002-11-11 2005-05-09 Pharmalett As Preparations for use as a therapeutic agent
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP4811576B2 (en) * 2005-03-31 2011-11-09 味の素株式会社 Moisture electrolyte supplement drink
JP4512013B2 (en) * 2005-09-07 2010-07-28 和光堂株式会社 Liquid beverage composition and method for producing the same
DE102006018293A1 (en) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pediatric amino acid solution for parenteral nutrition
EA030970B8 (en) * 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. COMPOSITION FOR RESTORING THE FINE INTESTINE FUNCTION, METHODS OF ITS PREPARATION AND APPLICATION
MX361647B (en) * 2013-03-11 2018-12-13 Univ Florida Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications.

Also Published As

Publication number Publication date
CN104093410B (en) 2018-04-27
MX368543B (en) 2019-10-07
US20210299076A1 (en) 2021-09-30
CA2863388A1 (en) 2013-08-15
EP2812007A1 (en) 2014-12-17
KR20140120941A (en) 2014-10-14
JP6084238B2 (en) 2017-02-22
JP2015506981A (en) 2015-03-05
EP2812007A4 (en) 2015-09-09
AU2013216871A1 (en) 2014-09-11
KR20200105525A (en) 2020-09-07
US20250073260A1 (en) 2025-03-06
AP2014007916A0 (en) 2014-09-30
US20150297636A1 (en) 2015-10-22
CN104093410A (en) 2014-10-08
EA201400827A1 (en) 2014-12-30
ES2862392T3 (en) 2021-10-07
BR112014019350A2 (en) 2017-06-20
AU2013216871B2 (en) 2017-08-17
AP3941A (en) 2016-12-16
BR112014019350B1 (en) 2020-09-24
CA2863388C (en) 2020-11-17
US20140377374A1 (en) 2014-12-25
HK1204290A1 (en) 2015-11-13
MX2014009557A (en) 2014-11-10
KR102262179B1 (en) 2021-06-07
EA034014B1 (en) 2019-12-19
BR112014019350A8 (en) 2017-07-11
WO2013119917A1 (en) 2013-08-15
EP2812007B1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
IN2014DN06737A (en)
MX2013004061A (en) Cyclosporin analogs.
MY187540A (en) Compounds active towards bromodomains
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX2019009132A (en) Synergistic bacterial compositions and methods of production and use thereof.
MX2015015518A (en) Methods and compositions for the treatment of cancer.
GB201106750D0 (en) Novel compounds
IN2015DN01156A (en)
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
HK1218560A1 (en) Compositions and methods
HK1220326A1 (en) Network-based microbial compositions and methods
EA201491617A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
TN2015000278A1 (en) Autotaxin inhibitors
MX2011007930A (en) Crystalline insulin-conjugates.
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
IN2012DN02177A (en)
IN2012DN02730A (en)
IN2012DN00754A (en)
MX343135B (en) Fumagillol type compounds and methods of making and using same.
GB201106743D0 (en) Novel compounds
PH12013500467A1 (en) Pharmaceutical composition
WO2015161243A3 (en) Beta-lactamases with improved properties for therapy
MX356755B (en) Fumigillol type compounds and methods of making and using same.